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Hepatocellular carcinoma (HCC) is the most important primary malignant liver 
disease. A large proportion of patients with advanced HCC have macrovascular 
invasion. HCC tends to infiltrate vascular structures, particularly the portal vein 
and its branches, and more rarely, the hepatic veins. The intravascular tumor 
thrombus can affect the inferior vena cava (IVC) or even the right atrium (RA), the 
latter having a poor prognosis.
CASE SUMMARY 
HCC is one of the most aggressive malignant tumors. Tumor thrombus (TT) 
formation in advanced HCC stages is common and usually involves the hepatic or 
portal veins. Herein, we report a 69-year-old woman who presented with dyspnea 
to the emergency department. A ventilation/perfusion lung scan was performed, 
ruling out pulmonary embolism. Hepatopulmonary syndrome and 
portopulmonary hypertension were discarded with contrasted echocardiography, 
but a mass in the RA was detected and confirmed by cardiac magnetic resonance 
imaging. Abdominal computed tomography showed a liver mass with a dynamic 
enhancement pattern compatible with HCC and an intraluminal IVC mass 
extending from the hepatic vein into the RA. HCC with TT expansion to IVC and 
RA is rare and indicates poor prognosis.
CONCLUSION 
HCC with TT expansion to IVC and RA is rare and indicates poor prognosis. 
There is no consensus about anticoagulation or other interventions in these 
patients.
Gomez-Puerto D et al. TT to the RA as the initial presentation of HCC
WJH https://www.wjgnet.com 1129 November 27, 2020 Volume 12 Issue 11
selected by an in-house editor and 
fully peer-reviewed by external 
reviewers. It is distributed in 
accordance with the Creative 
Commons Attribution 
NonCommercial (CC BY-NC 4.0) 
license, which permits others to 
distribute, remix, adapt, build 
upon this work non-commercially, 
and license their derivative works 
on different terms, provided the 
original work is properly cited and 
the use is non-commercial. See: htt
p://creativecommons.org/License
s/by-nc/4.0/
Manuscript source: Unsolicited 
manuscript
Specialty type: Gastroenterology 
and hepatology
Country/Territory of origin: Spain
Peer-review report’s scientific 
quality classification
Grade A (Excellent): 0 
Grade B (Very good): 0 
Grade C (Good): C, C 
Grade D (Fair): 0 
Grade E (Poor): 0
Received: July 12, 2020 
Peer-review started: July 12, 2020 
First decision: August 9, 2020 
Revised: August 23, 2020 
Accepted: September 15, 2020 
Article in press: September 15, 2020 
Published online: November 27, 
2020
P-Reviewer: Qi XS 
S-Editor: Gong ZM 
L-Editor: Filipodia 
P-Editor: Li JH
Key Words: Hepatocellular carcinoma; Alpha-fetoprotein; Tumor thrombus; Right atrium; 
Sorafenib; Case report
©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
Core Tip: Hepatocellular carcinoma (HCC) with tumor thrombus (TT) in the right 
atrium (RA) is an unusual but critical condition. There is no standard treatment strategy 
or consensus. Alpha-fetoprotein is reportedly a new alternative biomarker to RECIST 
in order to detect tyrosine kinase inhibitors response in HCC, and our case supports this 
hypothesis. We report this HCC case due to the exceptionality of a TT extending into 
the RA in a patient with stable cirrhosis. We believe this case will warn professionals 
when facing similar cases, so systemic treatment can be started in a timely fashion and 
the treatment response can be evaluated with a serial blood test in patients suffering 
from advanced HCC.
Citation: Gomez-Puerto D, Mirallas O, Vidal-González J, Vargas V. Hepatocellular carcinoma 
with tumor thrombus extends to the right atrium and portal vein: A case report. World J 




Hepatocellular carcinoma (HCC) is the most common primary malignant liver disease 
and the fourth most common cause of cancer-related deaths, resulting in a global 
incidence of approximately 800000 cases per year[1]. Currently, liver cancer is the 
second most lethal tumor, after pancreatic cancer, with a 5-year survival rate of 18%[2]. 
The most common cause of HCC worldwide is hepatitis B virus chronic infection, but 
in Western countries, hepatitis C virus infection, chronic alcohol consumption and 
non-alcoholic steatohepatitis predominate.
HCC primarily develops in cirrhotic livers, which is the major cause of death in this 
population[3]. HCC also tends to infiltrate vascular structures, particularly the portal 
vein and its branches, and more rarely, the hepatic veins. Intravascular tumor 
thrombus (TT) can progress and extend to the inferior vena cava (IVC) or even to the 
right atrium (RA), the latter having a worse prognosis compared with patients with TT 
in the portal or hepatic vein[4,5]. IVC/RA tumor thrombus is an infrequent event of 
patients with HCC, with a reported incidence of 3% to 4%. Its diagnosis is challenging 
due to the lack of specific clinical signs[6-8].
CASE PRESENTATION
Chief complaints
A 69-year-old woman complained about experiencing asthenia and dyspnea with 
dizziness and diaphoresis.
History of present illness
A 69-year-old woman arrived at the emergency department with a 15-d history of 
progressive asthenia, dyspnea on moderate exertion and progressive worsening 
shortness of breath associated with dizziness and diaphoresis.
History of past illness
The patient was diagnosed in 2005 with alcoholic cirrhosis, without any 
decompensation since 2011. She followed an adequate follow-up in the hepatology 
department of the hospital and she had been abstinent since the last decompensation. 
Her last abdominal Doppler-ultrasonography from May 2019 showed liver cirrhosis 
with signs of portal hypertension, mild ascites and cholelithiasis. Furthermore her last 
upper gastrointestinal endoscopy from June 2019 showed esophageal varices and 
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portal gastropathy. She also received treatment with beta-blockers and diuretics with 
good tolerance and adherence. Thereafter, she had a biological aortic valve 
replacement for severe aortic stenosis in December 2018, and since then, she remained 
asymptomatic.
Physical examination
The vital signs were within range and the physical examination was fairly normal. She 
had no chest discomfort or palpitations, orthopnea or an increase of the peripheral 
edema. She also denied having fever, chills, cough or expectoration, abdominal 
distention or any weight loss. In addition, she had a regular cardiac rhythm without 
cardiac murmur or rub noted, and the jugular venous pressure was not elevated. Her 
lungs were clear on auscultation and the oxygen saturation was correct without 
oxygen therapy. Her abdomen was also soft,  non-tender and had no 
hepatosplenomegaly or clear signs of ascites. Moreover, she had no leg swelling, 
bruising or petechiae. There was no clubbing or cyanosis of her feet or hands. Signs of 
liver cirrhosis were found on examination, such as spider angioma and mild palmar 
erythema.
Laboratory examinations
The blood test at admission revealed an impaired renal function with a creatinine of 
1.82 mg/dL and a glomerular filtration rate of 28 mL/min/1.73 m2, mild 
hyponatremia with sodium of 132.3 mmol/L, elevated pro-brain natriuretic peptide 
(923 pg/mL) and high D-dimer (917 ng/mL).
Imaging examinations
Her chest X-ray showed pathological signs. Due to the high suspicion of pulmonary 
embolism (PE) in a patient allergic to iodine, a ventilation/perfusion lung scan was 
performed, which did not exhibit any signs of PE. Contrasted echocardiography was 
requested to rule out portopulmonary hypertension or hepatopulmonary syndrome as 
the cause of the dyspnea of the patient. The test did not reveal signs of pulmonary 
hypertension nor shunts and showed a preserved systolic function (left ventricular 
ejection fraction [LVEF]: 58%) and a normally functioning prosthetic aortic valve. 
Unexpectedly, a mass at the posterior wall of the RA of 32 by 20 mm suggestive of an 
intracavitary thrombus was detected.
Further diagnostic work-up
Magnetic resonance imaging was performed to confirm this finding due to its higher 
sensitivity and specificity. The mass inside the RA coming from the liver through the 
IVC was noted. This image was suggestive of an infiltrating HCC tumor thrombus 
(TT) (Figure 1). With the previous premedication, an abdominal multiphase CT was 
finally performed, thereby confirming the presence of a lesion in segment VIII with 
extension to segments V and I, suggestive of hepatocarcinoma (Figure 2). Left 
suprahepatic vein thrombosis with extension to the IVC until the RA and thrombosis 
in the left portal vein was noted, suggestive of tumor infiltration (Figure 3). On further 
work-up, her alpha-fetoprotein level was 6856.1 ng/mL.
MULTIDISCIPLINARY EXPERT CONSULTATION
A multidisciplinary committee was held to decide treatment and further work-up.
FINAL DIAGNOSIS
The final diagnosis of the presented case is HCC with TT extended to the RA and 
portal vein.
TREATMENT
A multidisciplinary committee evaluated the patient and determined that she was not 
a candidate for surgical or ablative therapies. Thus, systemic treatment with sorafenib 
was started at 400 mg every 12 h and required dose reduction for asthenia. Given that 
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Figure 1 Magnetic resonance imaging coronal view of a polylobulated mass of 59 mm × 51 mm × 52 mm inside the right atrium (right 
arrow), which extends from the liver through the inferior vena cava (left arrow) to the inside of the right atrium occupying its lower-
posterior wall. These findings suggest as the first diagnostic possibility: A tumor thrombus of an advanced infiltrating hepatocellular carcinoma. Volumes and 
biventricular function within physiological parameters.
Figure 2  Computed tomography scan axial view shows a poorly defined liver injury with margins of 55 mm × 90 mm located in segment 
VIII and with extension to segment V and segment I, enhanced in arterial phase with fast venous phase washing.
the patient presented an extended TT, anticoagulation was introduced with low 
molecular weight heparin at a dose of 1 mg/kg every 12 h.
OUTCOME AND FOLLOW-UP
The patient was seen after 1 mo of being discharged, and she remained stable. She also 
showed an improved capacity for physical activities without any signs of embolism 
and diminished hepatomegaly in physical exploration. The dose of sorafenib was 
increased to a standard dose with positive tolerance. A non-contrast CT scan was 
completed 3 mo later (due to impaired kidney function). The limited evaluation 
presumed apparent stability of the tumoral mass (Figure 4). The alpha-fetoprotein 
level was 4156.1 ng/mL, thereby indicating a response to sorafenib. After 5 mo after 
receiving systemic therapy, the patient sought evaluation in the emergency 
department for being in a critical condition and was diagnosed with septic shock 
related to spontaneous bacterial peritonitis that ended fatally.
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Figure 3 Computed tomography scan coronal and sagittal views show a 55 mm × 90 mm mass in segment VIII with a tumor thrombus 
extending to the inferior vena cava (left arrow) and reaching up to right atrium (right arrow). Left intrahepatic portal thrombosis. Portal vein 
thrombosis with hypercaptation of the thrombus, suggestive of infiltrative tumor.
Figure 4 Non-contrast computed tomography scan axial view showing persistence of the heterogeneous lesion in the segment VIII seen 
previously, not delimitable in the current study. Hypodensity persists in the inferior vena cava and right atrium suggestive of tumor extension, with apparent 
small reduction, although the intravascular tumor thrombus cannot be properly determined in a non-contrast computed tomography.
DISCUSSION
HCC is the most common primary liver neoplasm. It is the fifth most frequently 
diagnosed cancer in men, and it is the ninth most commonly diagnosed cancer in 
women worldwide[9]. The development of HCC is intently related to the presence of 
chronic liver diseases.
The diagnosis of HCC can be difficult and often requires the use of one or more 
imaging approaches. Ideally, tumors should be detected when they are ≤ 2 cm so that 
all treatment options can be offered. Vascular invasion and tumor thrombosis 
formation are commonly seen in cases of advanced HCC due to the activation of 
hemostasis[10]. The incidence of vascular invasion increases with a larger tumor size, 
and it has been reported to be present in 82% of patients with serum AFP levels > 1000 
µg/L and a tumor diameter of > 5 cm[11]. IVC thrombosis is often asymptomatic, but 
symptoms related to portal hypertension can develop, for example, upper 
gastrointestinal bleeding, abdominal pain and ascites. Contrarily, the intra-atrial 
growth of HCC may not cause any symptoms per se but may lead to pulmonary 
thrombosis and pulmonary metastasis[12]. Advanced HCC with the invasion of the IVC 
and RA is exceptional, but it has been associated with poor prognosis and limited 
treatment options. In a retrospective study of 50 patients with advanced HCC with RA 
involvement, the median survival was only 2 mo with supportive care and only 
marginally improved to 4 mo with aggressive therapies[13].
The European Association for the Study of the Liver (EASL) recommends patients 
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with preserved liver function and minimally affected performance status (PS 0-2), 
stage C according to the Barcelona Clinic Liver Cancer Group (BCLC) and 
intermediate-stage (BCLC B) not eligible for locoregional therapies to undergo 
treatment with systemic therapy. Sorafenib, a multi-kinase inhibitor (TKI) was 
introduced in the EASL guidelines in 2008. Sorafenib showed a survival benefit, 
documenting prolonged median survival and a nearly 3-mo extension of time to 
radiologic progression, which represented a breakthrough in the management of 
HCC[14]. Alpha-fetoprotein has been reported as a new alternative biomarker to 
RECIST to detect a sorafenib response in HCC, with the optimum cut-off points 
varying in published literature but suggesting that higher pre-treatment (AFP > 200 
ng/mL) is associated with earlier recurrence and poorer overall survival[15,16]. Other 
experimental treatments were dismissed due to the age and medical history of the 
patient. Although sorafenib is the standard of care in these patients for more than a 
decade, further treatments and approaches have been undertaken in several reports as 
the resection of TT, the simultaneous resection of liver tumor and TT, external beam 
radiation therapy (EBRT), thalidomide treatment and transarterial chemoembolization 
(TACE). The postoperative survival period of patients with HCC and tumor thrombus 
in the RA varies from 18 d to 56 mo, with a mean survival of 20 mo[17]. In a 
retrospective cohort study of patients with HCC extending into the IVC/RA, treated 
with hepatectomy and thrombectomy, TACE and symptomatic treatment, the median 
survival was 19, 4.5 and 5 mo, respectively[17]. All these data indicate that removing the 
thrombus surgically combined with hepatectomy, or only TT extraction, might result 
in an improvement of survival in selected patients compared with other non-surgical 
procedures.
Radiofrequency ablation (commonly referred to as RFA) can result in long-term 
remission in small HCC. Nonetheless, performing RFA near the major vessels or 
diaphragm is difficult and challenging[18]. Several studies have validated that EBRT 
alone or combined with non-surgical treatment might achieve an excellent intrahepatic 
tumor control and a potential survival benefit of advanced HCC EBRT, presenting 
objective response rates ranging from 39% to 62% in patients with an associated 
macrovascular invasion[19]. The combination of TACE and RT has been beneficial 
compared with TACE alone for unresectable HCC in two meta-analyses[20,21]. 
Moreover, for major vessel invasion cases, combined TACE and RT had better OS and 
PFS than sorafenib, with a liver function not significantly worsened after treatment[22]. 
Further studies are crucial to accurately establish the incidence of adverse events and 
confirm these findings.
In our case, the patient was not a candidate for an invasive procedure; hence, 
systemic therapy with sorafenib was initiated. No predictive biomarkers of response to 
sorafenib or other TKI have been identified, and objective responses have been 
uncommon with the RECIST and modified RECIST criteria[23]. At a 3-mo follow-up, the 
patient improved symptoms with less dyspnea and asthenia, diminished 
hepatomegaly at physical exploration, a lower AFP levels and reached stable disease 
by CT scan.
CONCLUSION
HCC is one of the most common and aggressive malignant tumors, being the TT 
formation in advanced stages a relatively common complication usually involving the 
portal vein, and less frequently, the hepatic veins. Hepatopulmonary syndrome and 
portopulmonary hypertension are the two main causes of dyspnea that must be 
discarded in a cirrhotic patient.
Non-invasive imaging is an essential part of HCC diagnosis and contributes to 
primary liver tumor staging. When dynamic explorations demonstrate a typical 
diagnostic pattern, no further diagnostic invasive procedures are necessary. HCC TT 
expansion to IVC and RA is rare and indicates poor prognosis. There is no consensus 
on anticoagulation or other interventions in these patients. Treatment response has 
formerly been evaluated using the RECIST criteria by CT scan, but alpha-fetoprotein 
may be employed to consider sorafenib or any other TKI’s activity in HCC. Other 
treatment approaches could have been feasible as EBRT alone or combined with non-
surgical treatment, but more data are essential to further establish the status of EBRT 
for the management of HCC.
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